Author: Multibagger News

Bank of Montreal Triumphs in Appeals Court: $564 Million Verdict Overturned in Ponzi Scheme Case By Jonathan Stempel (Multibagger) – In a landmark victory, the Bank of Montreal (BMO) successfully convinced a U.S. appeals court to overturn a $564 million jury verdict against its subsidiary. This verdict was linked to the infamous $3.65 billion Ponzi scheme orchestrated by convicted Minnesota businessman Tom Petters. Appeals Court Cites Precedent in Similar Case Involving Bernard Madoff The 8th U.S. Circuit Court of Appeals in St. Paul, Minnesota, drew parallels to a similar case involving Bernard Madoff. The court ruled that the trustee assigned…

Uncover the Latest Insider Selling at Palantir Technologies – What Does it Mean for Investors? Palantir Technologies Inc. executive Taylor Ryan D. recently sold a significant amount of company stock, raising eyebrows among investors. The transactions, totaling over $5.4 million, were part of a preplanned trading arrangement to avoid insider trading accusations. Despite these sales, Taylor Ryan D. still holds a substantial number of shares in the company. In other news, Palantir reported a 27% increase in second-quarter earnings, with total revenue reaching $678.1 million. The company also raised its full-year revenue guidance. Analysts have mixed opinions on Palantir’s stock,…

Investing.com: Kamala Harris Extends Lead Over Donald Trump in Latest Poll – What Does This Mean for Your Investments? In a recent Multibagger/Ipsos poll, Vice President Kamala Harris has widened her lead over Republican Donald Trump in the race for the White House. Following a debate that many believe she won, Harris now leads Trump by 47% to 42% among registered voters for the upcoming Nov. 5 presidential election. This five-percentage-point advantage marks a slight increase from her previous four-point lead in a poll conducted in late August. The debate between Harris and Trump was widely seen as a victory…

Oracle Corporation (NYSE: ORCL) Sees Record Highs Amid AI-driven Revenue Surge: What This Means for Investors In a significant development for investors, Oracle Corporation (NYSE: ORCL) witnessed a remarkable surge in its share price during aftermarket trading on Thursday. The cloud computing giant’s stock soared by 6.4%, reaching an all-time high of $171.51. This impressive performance follows strong quarterly earnings and a strategic agreement with Amazon.com’s web services, underscoring Oracle’s robust market position and growth prospects. Oracle’s AI-Driven Revenue Forecasts Oracle has adjusted its fiscal 2026 revenue forecast upward to $66 billion from a previous estimate of $65 billion, surpassing…

Diego Maradona Death Trial Postponed Until March: Latest Updates The highly anticipated trial of eight health workers charged with “homicide by negligence” in the death of legendary footballer Diego Maradona has been postponed from October to March, according to Argentine media reports. The court in San Isidro, near Buenos Aires, has granted the request of three defendants to delay the trial for a second time. Originally set to begin on October 1, the trial will now commence on March 11, as reported by Argentine newspaper La Nacion. Maradona, who led Argentina to a World Cup victory in 1986, passed away…

Antal Rohit Desai, Director at Procept BioRobotics Corp (NASDAQ:PRCT), Sells Over $9.3 Million in Company Stock Procept BioRobotics Corp (NASDAQ:PRCT) director Antal Rohit Desai has recently sold a significant amount of company stock, totaling over $9.3 million. The sales, which occurred over several days in September, were part of a pre-arranged trading plan to avoid accusations of insider trading. Desai sold shares at prices ranging from $75.7813 to $80.6477 per share. Despite the sales, he still indirectly holds a substantial number of shares through The 2:22 DNA Trust. Procept BioRobotics specializes in surgical and medical instruments and apparatus, and has…

The Ultimate Guide to Trump vs. Harris Debate Drama: What You Need to Know In a shocking turn of events, former President Donald Trump has declared that there will be no second debate with Vice President Kamala Harris after a contentious showdown earlier this week. Trump took to Truth.Social to launch a scathing attack on Harris and President Joe Biden, accusing them of fueling inflation and economic instability. Despite Trump’s claims of victory in the late-Tuesday debate with Harris, analysts widely viewed Harris as the clear winner in a heated exchange on ABC News. The debate touched on hot-button issues…

Breaking News: U.S. Authorities to File Criminal Charges Over Alleged Iranian Hack on Trump Campaign Inside the Investigation: Hack Allegations, Iranian Denial, and FBI’s Pursuit Introduction In a significant development that could have far-reaching implications, U.S. authorities are on the brink of filing criminal charges in response to allegations that the Trump campaign’s internal communications were hacked. The Trump campaign had previously pointed a finger at the Iranian government for this breach, a claim that Tehran vehemently denies. The Washington Post, citing sources close to the matter, has brought this unfolding story into the spotlight. Key Details of the Investigation…

As the top investment manager and financial market journalist, I bring you the latest update on the highly anticipated debate between former President Donald Trump and Vice President Kamala Harris. In a surprising turn of events, Trump has declared that there will be no second debate with Harris, citing his victory in the recent debate that was widely seen as a Harris triumph. Trump took to Truth.Social to launch a scathing attack on Harris and President Joe Biden, accusing them of fueling inflation and destabilizing the economy. Despite calls for a rematch from Harris’s camp, Trump remains adamant that he…

Opaleye Management Inc. Makes Bullish Moves with Eton Pharmaceuticals Stock Purchases Opaleye Management Inc., a prominent investor in Eton Pharmaceuticals Inc. (NASDAQ:), recently acquired a substantial amount of the company’s common stock, signaling a positive outlook on the pharmaceutical company. The investment firm made purchases totaling over half a million dollars across two days, boosting its holdings in Eton Pharmaceuticals significantly. The transactions saw Opaleye Management Inc. buying 50,000 shares at $4.65 each on September 10, followed by additional purchases at the same price. The next day, the firm continued to buy Eton Pharmaceuticals shares, acquiring 45,000 shares at $4.75…